Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
GlaxoSmithKline Clicks With Crick
by Alex Scott
July 20, 2015
| A version of this story appeared in
Volume 93, Issue 29
GlaxoSmithKline and London’s new Francis Crick Institute have agreed to co-develop treatments for diseases including HIV, malaria, and cancer. Both parties will contribute 10 researchers to the collaboration, which by 2016 aims to have up to 15 projects. GSK will provide the partnership with access to its library of 2 million compounds with interesting pharmaceutical properties. The two will work together in GSK’s R&D center in Stevenage, just north of London, and also at Crick’s $1 billion center after it opens in London later this year.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter